{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:41:58Z","timestamp":1793889718962,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01715-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:56:09Z","timestamp":1751378169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"18","author":[{"given":"N\u00e9stor","family":"Tirado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Fidyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Mansilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garcia-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Mart\u00ednez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Vinyoles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Alcain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Garc\u00eda-Peydr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleia","family":"Roca-Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcis","family":"Fernandez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Guerrero-Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00efda","family":"Falg\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Velasco-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Panelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Mulens-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostol","family":"Apostolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Europa Azucena","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binje","family":"Vick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmela","family":"Jeremias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Caye-Eude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Cav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eul\u00e0lia","family":"Genesc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Escudero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ram\u00edrez-Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Torrebadell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor M","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L","family":"Toribio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1715_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"MR Litzow","year":"2015","unstructured":"Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126:833\u201341.","journal-title":"Blood"},{"key":"1715_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199\u2013209.","journal-title":"Lancet Oncol."},{"key":"1715_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077\u201384.","journal-title":"Blood"},{"key":"1715_CR4","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.","journal-title":"Blood"},{"key":"1715_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"1715_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N. Engl. J. Med."},{"key":"1715_CR7","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"1715_CR8","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.","journal-title":"Sci Transl Med."},{"key":"1715_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20\u20138.","journal-title":"Nat Med."},{"key":"1715_CR10","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","volume":"32","author":"M Alcantara","year":"2018","unstructured":"Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32:2307\u201315.","journal-title":"Leukemia"},{"key":"1715_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2019.00126","volume":"9","author":"LD Scherer","year":"2019","unstructured":"Scherer LD, Brenner MK, Mamonkin M. chimeric antigen receptors for T-cell malignancies. Front Oncol. 2019;9:126.","journal-title":"Front Oncol."},{"key":"1715_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell\u2013directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983\u201392.","journal-title":"Blood"},{"key":"1715_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285\u201396.","journal-title":"Blood"},{"key":"1715_CR14","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348\u201360.","journal-title":"Blood Adv."},{"key":"1715_CR15","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32:1970\u201383.","journal-title":"Leukemia"},{"key":"1715_CR16","doi-asserted-by":"publisher","first-page":"e99442","DOI":"10.1172\/jci.insight.99442","volume":"3","author":"J Rasaiyaah","year":"2018","unstructured":"Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3:e99442-99442.","journal-title":"JCI Insight."},{"key":"1715_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140:619\u201329.","journal-title":"Blood"},{"key":"1715_CR18","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, Phase I Trial. J Clin Oncol. 2021;39:3340\u201351.","journal-title":"J. Clin. Oncol."},{"key":"1715_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007.","journal-title":"Cell Res."},{"key":"1715_CR20","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood"},{"key":"1715_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16:34.","journal-title":"J Hematol Oncol."},{"key":"1715_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. N Engl J Med. 2024;390:1467\u201380.","journal-title":"N. Engl. J. Med."},{"key":"1715_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23:1416\u201323.","journal-title":"Nat. Med."},{"key":"1715_CR24","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes. J Clin Invest. 2017;127:3462\u201371.","journal-title":"J. Clin. Invest."},{"key":"1715_CR25","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez D, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133:2291\u2013304.","journal-title":"Blood"},{"key":"1715_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","volume":"14","author":"J Shi","year":"2021","unstructured":"Shi J, et al. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol. 2021;14:162.","journal-title":"J Hematol Oncol."},{"key":"1715_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.2021013648","volume":"140","author":"PM Maciocia","year":"2022","unstructured":"Maciocia PM, et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood. 2022;140:25\u201337.","journal-title":"Blood"},{"key":"1715_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41467-024-45854-3","volume":"15","author":"M Ferrari","year":"2024","unstructured":"Ferrari M, et al. Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies. Nat Commun. 2024;15:1583.","journal-title":"Nat. Commun."},{"key":"1715_CR29","doi-asserted-by":"publisher","first-page":"e005333","DOI":"10.1136\/jitc-2022-005333","volume":"10","author":"A Jim\u00e9nez-Reinoso","year":"2022","unstructured":"Jim\u00e9nez-Reinoso A, et al. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. J Immunother Cancer. 2022;10:e005333.","journal-title":"J. Immunother Cancer"},{"key":"1715_CR30","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1182\/blood-2003-06-1812","volume":"103","author":"NE Annels","year":"2004","unstructured":"Annels NE. Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL. Blood. 2004;103:2806\u20138.","journal-title":"Blood"},{"key":"1715_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/path.3015","volume":"226","author":"L Mirandola","year":"2012","unstructured":"Mirandola L, et al. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2012;226:713\u201322.","journal-title":"J Pathol"},{"key":"1715_CR32","doi-asserted-by":"publisher","first-page":"e000896","DOI":"10.1136\/jitc-2020-000896","volume":"8","author":"T Velasco-Hernandez","year":"2020","unstructured":"Velasco-Hernandez T, et al. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4\u20131BB-based CAR targeting a membrane-distal CD22 epitope. J Immunother Cancer. 2020;8:e000896.","journal-title":"J. Immunother. Cancer"},{"key":"1715_CR33","doi-asserted-by":"crossref","unstructured":"Lefranc, M.-P. Antibody Informatics: IMGT, the International ImMunoGeneTics Information System. Microbiol Spectr. 2014;2.","DOI":"10.1128\/microbiolspec.AID-0001-2012"},{"key":"1715_CR34","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463\u201371.","journal-title":"J. Virol."},{"key":"1715_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies. Mol Ther. 2021;29:636\u201344.","journal-title":"Mol Ther."},{"key":"1715_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","volume":"30","author":"SR Zanetti","year":"2022","unstructured":"Zanetti SR, et al. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Mol Ther J Am Soc Gene Ther. 2022;30:550\u201363.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"1715_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-023-01803-0","volume":"22","author":"E Bahrami","year":"2023","unstructured":"Bahrami E, et al. Combined proteomics and CRISPR-Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Mol Cancer. 2023;22:107.","journal-title":"Mol Cancer"},{"key":"1715_CR38","first-page":"1783","volume":"9","author":"MC Bene","year":"1995","unstructured":"Bene MC, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783\u20136.","journal-title":"Leukemia."},{"key":"1715_CR39","doi-asserted-by":"publisher","first-page":"eabl4896","DOI":"10.1126\/science.abl4896","volume":"376","author":"THE TABULA SAPIENS CONSORTIUM","year":"2022","unstructured":"THE TABULA SAPIENS CONSORTIUM. The Tabula Sapiens: A multiple-organ, single-cell transcriptomic atlas of humans. Science. 2022;376:eabl4896.","journal-title":"Science."},{"key":"1715_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/leu.2017.294","volume":"32","author":"C Prieto","year":"2018","unstructured":"Prieto C, et al. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia. 2018;32:633\u201344.","journal-title":"Leukemia"},{"key":"1715_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/emmm.201201703","volume":"5","author":"K Rehe","year":"2013","unstructured":"Rehe K, et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med. 2013;5:38\u201351.","journal-title":"EMBO Mol. Med."},{"key":"1715_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-15-0675","volume":"6","author":"A Trinquand","year":"2016","unstructured":"Trinquand A, et al. Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia. Cancer Discov. 2016;6:972\u201385.","journal-title":"Cancer Discov."},{"key":"1715_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-019-0801-y","volume":"12","author":"LC Fleischer","year":"2019","unstructured":"Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12:14.","journal-title":"J Hematol Oncol."},{"key":"1715_CR44","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood.2020005185","volume":"136","author":"D Stenger","year":"2020","unstructured":"Stenger D, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR. Blood. 2020;136:1407\u201318.","journal-title":"Blood"},{"key":"1715_CR45","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad AD, et al. Frequent aneuploidy in primary human T cells after CRISPR\u2013Cas9 cleavage. Nat Biotechnol. 2022;40:1807\u201313.","journal-title":"Nat. Biotechnol."},{"key":"1715_CR46","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, et al. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. N Engl J Med. 2024;390:2047\u201360.","journal-title":"N. Engl. J. Med."},{"key":"1715_CR47","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984\u20139.","journal-title":"Nat. Med."},{"key":"1715_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2024;390:584\u20136.","journal-title":"N. Engl. J. Med."},{"key":"1715_CR49","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, et al. CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma. Blood. 2023;142:6939\u20136939.","journal-title":"Blood"},{"key":"1715_CR50","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida CA, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 2023;186:4567-4582.e20.","journal-title":"Cell"},{"key":"1715_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood.V114.22.324.324","volume":"114","author":"D Hoelzer","year":"2009","unstructured":"Hoelzer D, et al. Successful subtype oriented treatment strategies in adult T-All; results of 744 patients treated in three consecutive GMALL studies. Blood. 2009;114:324.","journal-title":"Blood"},{"key":"1715_CR52","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","volume":"4","author":"S Leong","year":"2020","unstructured":"Leong S, et al. CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy. Blood Adv. 2020;4:4665\u20138.","journal-title":"Blood Adv."},{"key":"1715_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol."},{"key":"1715_CR54","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0","volume":"30","author":"M-A Wurbel","year":"2000","unstructured":"Wurbel M-A, et al. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol. 2000;30:262\u201371.","journal-title":"Eur. J. Immunol."},{"key":"1715_CR55","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood.V94.7.2533.419k37_2533_2536","volume":"94","author":"BS Youn","year":"1999","unstructured":"Youn BS, Kim CH, Smith FO, Broxmeyer HE. TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6\/CCR9 as a specific receptor. Blood. 1999;94:2533\u20136.","journal-title":"Blood"},{"key":"1715_CR56","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.4049\/jimmunol.162.10.5671","volume":"162","author":"\u00c1 Zaballos","year":"1999","unstructured":"Zaballos \u00c1, Guti\u00e9rrez J, Varona R, Ardav\u00edn C, M\u00e1rquez G. Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol. 1999;162:5671\u20135.","journal-title":"J. Immunol."},{"key":"1715_CR57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494\u2013507.","journal-title":"Nat. Rev. Cancer"},{"key":"1715_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/icvts\/ivu343","volume":"20","author":"J Roosen","year":"2015","unstructured":"Roosen J, Oosterlinck W, Meyns B. Routine thymectomy in congenital cardiac surgery changes adaptive immunity without clinical relevance. Interact Cardiovasc Thorac Surg. 2015;20:101\u20136.","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"1715_CR59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2249.2006.03139.x","volume":"145","author":"H Torfadottir","year":"2006","unstructured":"Torfadottir H, et al. Evidence for extrathymic T cell maturation after thymectomy in infancy. Clin Exp Immunol. 2006;145:407\u201312.","journal-title":"Clin Exp Immunol."},{"key":"1715_CR60","doi-asserted-by":"publisher","unstructured":"Keshav, S. & Wendt, E. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin. Exp. Gastroenterol. 2015;119. https:\/\/doi.org\/10.2147\/CEG.S48305.","DOI":"10.2147\/CEG.S48305"},{"key":"1715_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaut.2016.01.001","volume":"68","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, et al. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. J Autoimmun. 2016;68:98\u2013104.","journal-title":"J. Autoimmun."},{"key":"1715_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1124\/jpet.110.169714","volume":"335","author":"MJ Walters","year":"2010","unstructured":"Walters MJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010;335:61\u20139.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1715_CR63","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/apt.13398","volume":"42","author":"BG Feagan","year":"2015","unstructured":"Feagan BG, et al. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42:1170\u201381.","journal-title":"Aliment Pharmacol Ther."},{"key":"1715_CR64","doi-asserted-by":"publisher","unstructured":"Brillembourg, H. et al. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br J Haematol.2024https:\/\/doi.org\/10.1111\/bjh.19348","DOI":"10.1111\/bjh.19348"},{"key":"1715_CR65","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22:976\u201395.","journal-title":"Nat. Rev. Drug Discov."},{"key":"1715_CR66","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat. Med."},{"key":"1715_CR67","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks V, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138:1081\u20135.","journal-title":"Blood"},{"key":"1715_CR68","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3892\/or.2014.2998","volume":"31","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, et al. CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma. Oncol Rep. 2014;31:1629\u201336.","journal-title":"Oncol. Rep."},{"key":"1715_CR69","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1089\/dna.2015.3104","volume":"35","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, et al. CCL25\/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines. DNA Cell Biol. 2016;35:348\u201357.","journal-title":"DNA Cell Biol."},{"key":"1715_CR70","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s11605-009-1002-8","volume":"13","author":"X Shen","year":"2009","unstructured":"Shen X, et al. CC Chemokine Receptor 9 Enhances Proliferation in Pancreatic Intraepithelial Neoplasia and Pancreatic Cancer Cells. J Gastrointest Surg. 2009;13:1955\u201362.","journal-title":"J. Gastrointest. Surg."},{"key":"1715_CR71","doi-asserted-by":"publisher","first-page":"10170","DOI":"10.18632\/oncotarget.2526","volume":"5","author":"P Gupta","year":"2014","unstructured":"Gupta P, et al. CCR9\/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014;5:10170\u20139.","journal-title":"Oncotarget"},{"key":"1715_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13000-015-0341-x","volume":"10","author":"Y Zhong","year":"2015","unstructured":"Zhong Y, et al. Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma. Diagn Pathol. 2015;10:101.","journal-title":"Diagn. Pathol."},{"key":"1715_CR73","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1078-0432.CCR-07-2025","volume":"14","author":"FF Amersi","year":"2008","unstructured":"Amersi FF, et al. Activation of CCR9\/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine. Clin Cancer Res. 2008;14:638\u201345.","journal-title":"Clin. Cancer Res."},{"key":"1715_CR74","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1059","author":"S Singh","year":"2011","unstructured":"Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011. https:\/\/doi.org\/10.3892\/ijo.2011.1059.","journal-title":"Int. J. Oncol."},{"key":"1715_CR75","doi-asserted-by":"publisher","first-page":"eaax4690","DOI":"10.1126\/sciadv.aax4690","volume":"6","author":"H Chen","year":"2020","unstructured":"Chen H, et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9 + T cells. Sci Adv. 2020;6:eaax4690.","journal-title":"Sci Adv."},{"key":"1715_CR76","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/bloodadvances.2022008762","volume":"7","author":"VM Perriello","year":"2023","unstructured":"Perriello VM, et al. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Adv. 2023;7:2855\u201371.","journal-title":"Blood Adv."},{"key":"1715_CR77","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro-Oncol. 2022;24:1318\u201330.","journal-title":"Neuro-Oncol."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01715-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01715-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01715-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:07:02Z","timestamp":1751378822000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01715-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01715-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.02.610843","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PM is a cofounder of OneChain Immunotherapeutics, a spin-off company from the Josep Carreras Leukemia Research Institute which has licensed the CCR9 binder (PCT\/EP2024\/053734). The remaining authors report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}